IL6 and breast carcinoma: Metformin disrupts tumor-stromal crosstalk by inactivating CAF and preventing their subsequent secretion of pro-tumoral factors such as SDF-1 and IL-8 in breast cancer or IL-6 in ovarian cancer [89,90].